Financing

VectorY Therapeutics secures EUR 74.5 million for vectorized antibody pipeline

VectorY Therapeutics raised EUR 74.5 million, about $83.5 million, from a mix of returning and first-time backers. The money funds its ALS candidate VTx-002 to final results from PIONEER-ALS, a phase 1/2 trial now enlarged to 36 patients from 12, and also supports the Huntington's program VTx-003.

Written by Gosset from public sources. Source types: Press release. Sources are available to Gosset users. Log in to see them.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call